Minerva Neurosciences, Inc.

Report azionario NasdaqCM:NERV

Capitalizzazione di mercato: US$231.1m

Minerva Neurosciences Gestione

Criteri Gestione verificati 1/4

Minerva Neurosciences Il CEO è Remy Luthringer, nominato in Nov2014, e ha un mandato di 11.58 anni. la retribuzione annua totale è $ 9.35M, composta da 7.2% di stipendio e 92.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.4% delle azioni della società, per un valore di $ 916.69K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 10.2 anni e 0.3 anni.

Informazioni chiave

Remy Luthringer

Amministratore delegato

US$9.4m

Compenso totale

Percentuale dello stipendio del CEO7.22%
Mandato del CEO11.6yrs
Proprietà del CEO0.4%
Durata media del management10.2yrs
Durata media del Consiglio di amministrazioneless than a year

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Oct 17

Minerva says FDA declined to accept marketing application for schizophrenia drug

Minerva Neurosciences (NASDAQ:NERV), a biotech focused on central nervous system diseases, announced Monday that the FDA issued a "refusal to file" letter regarding its marketing application for roluperidone, a treatment targeted at schizophrenia patients. Without detailing reasons for the refusal, NERV said that the FDA had notified the company could request a Type A meeting to discuss the contents of the letter. Schizophrenia is a mental illness affecting an estimated 20M people globally.  "We are disappointed that the FDA has not accepted our NDA for roluperidone," Chief Executive Remy Luthringer remarked, adding, "the company intends to request a Type A meeting and looks forward to continued discussions with the FDA." NERV shares are currently on hold for trading.
Seeking Alpha • Aug 29

Minerva Neurosciences: Biotech On The Move

Summary NERV stock price has been on fire in recent days. Minerva Neurosciences' troubled roluperidone is just about its lone project candidate. Minerva's financial condition is fraught but adequate for the situation. Minerva Neurosciences (NERV) is a name I have not followed, nor even heard of, until its recent run. Its new price action makes for an interesting story. In this article I review its standing as an investment after its wild upswing. Minerva's shares traded with real urgency during the week of 08/22/2022 For Minerva the week preceding this 08/28/2022 writing was the week that was. After closing on Friday 08/19/2022 at $3.11, it hit a high of $5.19 on Monday 08/22/2022. Before market open on 08/22/2022, Minerva filed its long delayed, as hereafter discussed, NDA for its for roluperidone for the treatment of negative symptoms in patients with schizophrenia. Also on Monday, Steve Cohen and Point72 filed a joint ownership 13G advising of acquisition of 470,000 shares, an 8.8% interest in Minerva. After resting a bit on Tuesday, digesting the news, by Wednesday 08/24/2022, Minerva's jets were firing again full steam, hitting a share price high of $8.58. Its volume Wednesday was exceptional leaping to >82 million shares. Thursday 08/25/2022 was another consolidation day. On Friday 08/26/2022 it hit a peak for the week at $10.89, closing out the week at $10.33 on a volume of >61 million shares. Its price for the week from the previous Friday trough of $3.11 to its following Friday peak of $10.89 reflected an increase of >250%. What has Minerva's longer term share movement looked like? The chart below draws out Minerva's share dynamics over recent years: NERV data by YCharts Minerva's steep 05/2020 downdraft (>-81%) following its negative data release for its phase 3 trial for roluperidone in treatment of negative symptoms in schizophrenia dwarfs its recent upswing. Minerva Neurosciences is a one trick pony with the one trick not yet fully mastered When trying to understand a new biotech name, I usually start by trying to run down its pipeline. For Minerva this endeavor was more difficult than typical. Its 2022 10-K atypically included zero help in this regard. I moved on to check out its website. Again atypically, it includes no entry for its "pipeline" as such. However when I searched for the word "pipeline" it took me to its "programs". There I found the following rather desolate entry which satisfied my need for a pipeline: minervaneurosciences.com As a preclinical program, one of many targeting Parkinson's Disease, I give Minerva's MIN-301 no real consideration. By my assessment MIN-301 is inconsequential in any current evaluation of Minerva. So Minerva is all about roluperidone (MIN-101) in treatment of negative symptoms of schizophrenia. Despite its rough road back with its phase 3 data release in 05/2020, Minerva is motoring ahead with this as fast as it can. Its progress has been halting at best as reflected by the following Seeking Alpha news items: 11/02/2020 Minerva schedules a Type C meeting with the FDA to advance its position of confidence in roluperidone and to discuss and define a forward path; 12/01/2020 Minerva and FDA at odds, with Minerva contending that the totality of the data demonstrates substantial evidence of effectiveness of the 64 mg dose, while FDA considers situation problematic for several reasons including inadequately powered phase 3 to show effectiveness; 05/11/2020 Minerva posts results from its Open-Label Extension [OLE] of its late stage roluperidone trial that it characterized as highly favorable in terms of longer term improvements in patients overall functioning "with few serious adverse events and no evidence of somnolence, extrapyramidal side effects or weight gain"; 09/30/2021 Minerva reported a positive bioequivalence study for roluperidone; 11/03/2021 FDA rebuffs Minerva request for a pre-NDA meeting for roluperidone, instead suggesting that a "Type C guidance meeting would be more appropriate to discuss the evidence for use of roluperidone as monotherapy". It seems that Minerva finally got the point and went ahead with a Type C meeting. On 04/07/2022 it reported minutes from an 03/02/2022 Type C roluperidone meeting, purposed so that Minerva could obtain: ...the FDA’s agreement on the use of roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia in the subgroup of patients with moderate to severe negative symptoms and stable positive symptoms. On 04/13/2022 it set up a slide deck with its "Roluperidone Update Presentation". This was the material it used to illustrate its 04/03/2022 webcast with its Roluperidone Update; as I write on 08/28/2022 this webcast is still on Minerva's website. The summary slide at the close of this presentation addressed key issues raised by the FDA as follows: seekingalpha.com As I write on 08/28/2022, this is where the situation stands with Minerva's 08/22/2022 filing of its roluperidone NDA. Next stop for roluperidone is FDA decision on whether to approve its filing; we should hear on this within 60 days, likely late October. NERV will need to raise additional funds over its near to mid term Minerva seems to have given up on earnings conference calls, having run its last earnings call for Q3, 2021. This is unfortunate because such calls provide a nice add of color to straight earnings press releases and 10-K/Q's. But for whatever reason, current Minerva investors must make do with what's available. As for Minerva's Q2, 2022 earnings press release, it lists the essentials. Most notably it listed Minerva's bare bones liquidity position as of 06/30/2022 at ~$49.9 million. This compares to its cash, cash equivalents and restricted cash of ~$60.9 million as of 12/31/2021. Minerva's Q2, 2022 Statement of Operation below lists it most recent quarterly and semiannual operating expenses as follows: Minerva Q2, 2022 statement of operations excerpt (sec.gov)
Seeking Alpha • Aug 22

Minerva stock rises on filing for FDA approval of schizophrenia therapy

Minerva Neurosciences (NASDAQ:NERV) filed an application to the U.S. Food and Drug Administration (FDA) seeking approval of roluperidone to treat negative symptoms in patients with schizophrenia. The company's new drug application (NDA) was backed by data from two late-stage studies (MIN-101C03 and MIN-101C07) in patients with moderate to severe negative symptoms and stable positive symptoms of schizophrenia. Minerva is seeking approval for the 64-mg dose of roluperidone. "While positive symptoms of schizophrenia are generally well managed with antipsychotics, negative symptoms are often the main burden of illness and can impact the patients’ quality of life as a result of disabilities caused by impaired vocational and social skills," said Executive Chairman and CEO Remy Luthringer. The company noted that there are currently no treatments approved for negative symptoms of schizophrenia in the U.S. NERV +7.89% to $3.35 premarket Aug. 22
Articolo di analisi • Jun 22

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Articolo di analisi • Jan 26

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Oct 02

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Mar 03

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Minerva Neurosciences, Inc. ( NASDAQ:NERV ) shareholders should be happy to see the share price up 15% in the last...
Articolo di analisi • Jan 27

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

A look at the shareholders of Minerva Neurosciences, Inc. ( NASDAQ:NERV ) can tell us which group is most powerful...
Articolo di analisi • Dec 23

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Nov 18

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Minerva Neurosciences, Inc. (NASDAQ:NERV) shareholders should be happy to see the share price up 12% in the last...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Remy Luthringer rispetto agli utili di Minerva Neurosciences?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$415m

Dec 31 2025US$9mUS$675k

-US$293m

Sep 30 2025n/an/a

-US$14m

Jun 30 2025n/an/a

US$11m

Mar 31 2025n/an/a

US$6m

Dec 31 2024US$1mUS$649k

US$1m

Sep 30 2024n/an/a

-US$3m

Jun 30 2024n/an/a

-US$34m

Mar 31 2024n/an/a

-US$32m

Dec 31 2023US$2mUS$624k

-US$30m

Sep 30 2023n/an/a

-US$28m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$600k

-US$32m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$51m

Dec 31 2021US$1mUS$585k

-US$50m

Sep 30 2021n/an/a

-US$36m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

US$5m

Dec 31 2020US$2mUS$565k

US$2m

Sep 30 2020n/an/a

-US$21m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$69m

Dec 31 2019US$1mUS$543k

-US$72m

Compensazione vs Mercato: La retribuzione totale di Remy ($USD 9.35M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.66M ).

Compensazione vs guadagni: La retribuzione di Remy è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Remy Luthringer (65 yo)

11.6yrs
Mandato
US$9,354,184
Compensazione

Dr. Remy Luthringer, Ph D., serves as a Clinical Advisor to the Medicxi investment team and a Member of the Co-Founding team at Medicxi Ventures (UK) LLP. He has played an active role in several Index Vent...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Remy Luthringer
Executive Chairman11.6yrsUS$9.35m0.40%
$ 916.7k
Frederick Ahlholm
Senior VP4.7yrsUS$2.47m0.038%
$ 86.9k
Joseph Reilly
Senior VP & COO11.9yrsUS$1.49mNessun dato
William Boni
Vice President of Investor Relations & Corporate Communications10.8yrsNessun datoNessun dato
James O'Connor
Chief Business Officer & General Counselless than a yearNessun datoNessun dato
Michael Davidson
Member of Scientific Advisory Board & Chief Medical Officer9.5yrsUS$657.47kNessun dato
10.2yrs
Durata media
62.5yo
Età media

Gestione esperta: Il team dirigenziale di NERV è esperto e expertise (durata media dell'incarico 10.2 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Remy Luthringer
Executive Chairman11.6yrsUS$9.35m0.40%
$ 916.7k
Michael Davidson
Member of Scientific Advisory Board & Chief Medical Officerno dataUS$657.47kNessun dato
G. van Heek
Independent Director11.9yrsUS$233.00k0.0055%
$ 12.6k
Hans Hasler
Independent Director8.5yrsUS$235.00k0.0027%
$ 6.2k
Philip Harvey
Member of Scientific Advisory Boardno dataNessun datoNessun dato
David Kupfer
Lead Independent Director10.6yrsUS$259.50k0.051%
$ 118.7k
Inder Kaul
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Fouzia Laghrissi-Thode
Independent Director11.1yrsUS$227.25k0%
$ 0
Oliver Howes
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Brian Kirkpatrick
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Gregory Strauss
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Inderjit Kaul
Directorless than a yearUS$1.35mNessun dato
0.3yrs
Durata media
70yo
Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di NERV non è considerato esperto (durata media del mandato 0.3 anni), il che suggerisce un nuovo consiglio.

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/08 18:05
Prezzo dell'azione a fine giornata2026/06/05 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Minerva Neurosciences, Inc. è coperta da 5 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Brian SkorneyBaird
Jason ButlerCitizens JMP Securities, LLC
Douglas TsaoH.C. Wainwright & Co.